Research Examines Efficacy Of Sglt2 Inhibitor As 2ndline Diabetes Therapy | Latest News RSS feed

Research Examines Efficacy Of Sglt2 Inhibitor As 2ndline Diabetes Therapy - Latest News

EASE: Empagliflozin Beneficial in Type 1 Diabetes, DKA a Risk

Findings from the Empagliflozin as Adjunctive to Insulin Therapy (EASE) program were presented October 4 here at the European Association for the Study of Diabetes (EASD) 2018 Annual Meeting and ... read more

Merck's Diabetes Pipeline Candidates Are Sure Bets; Only A Matter Of When

Diabetes is a global health problem, and more than 29 million people in the U.S. have diabetes. This article examines the Merck (NYSE ... Ertugliflozin is a sodium-glucose co-transporter 2 (SGLT2) ... read more

Islet Sciences, Inc. Highlights Remogliflozin Etabonate as Novel Treatment for Non-alcoholic Steatohepatitis (NASH)

Remogliflozin etabonate is uniquely positioned as an effective therapy for NAFLD/NASH due to its proven insulin-sensitizing activity as a selective SGLT2 ... dependent diabetes; first-in-class ... read more

Looking for another news?

Boehringer Ingelheim and Lilly present full results from EASE Phase III program for empagliflozin as adjunct to insulin in type 1 diabetes

Empagliflozin is an SGLT2 inhibitor used along with diet and exercise ... this heritage by working to meet the diverse needs of people with diabetes and those who care for them. Through research and ... read more

Saxagliptin: A Therapy Option in Diabetes and Renal Failure

Saxagliptin ... efficacy and safety of saxagliptin to inform clinicians when formulating treatment strategies for their patients with concomitant type 2 diabetes and renal impairment," they conclude. ... read more

Enhancing pediatric clinical trial feasibility through the use of Bayesian statistics

Pediatric clinical trials commonly experience recruitment challenges including limited number of patients and investigators, inclusion/exclusion criteria that further reduce the patient pool, and a ... read more

From the Apple Watch to Heart Failure at Annual Cardiologists' Meeting

In recent years, the big news on the first day of the American College of Cardiology (ACC) Scientific Session and Exposition has involved a therapy ... class of type 2 diabetes (T2D) therapies, sodium ... read more

Buy vTv Therapeutics For Its Novel Alzheimer's And Anti-Diabetic Drug Candidates.

Extensive research has now shown that dysfunction of the GK enzyme may lead to development of type II diabetes. In preclinical studies, drugs targeting the activation of GK enzyme have shown efficacy ... read more

Real-world data finds patients feel better on Entresto, says Novartis

At the moment much of the interest in new drug therapies for heart failure lies in the use of antidiabetic drugs and particularly SGLT2 inhibitors such ... in patients who do not have diabetes. “It is ... read more

Refocused On Success 2013

Read says during 2012, Pfizer continued to pursue “bolt-on” business development opportunities to supplement its research efforts ... position in diabetes care with the introduction of ertugliflozin, ... read more

5 Things to Look for at the American College of Cardiology Scientific Session

examines ... for SGLT2 Inhibitors Featured research from the CVD-REAL study will report on hospitalization rates for heart failure on sodium glucose co-transporter-2 (SGLT2) inhibitors, a new and ... read more

FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us